{"id":"W3135310517","doi":"10.1200/jco.2021.39.6_suppl.tps266","title":"DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University; Ottawa Hospital; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Placebo; Internal medicine; Docetaxel; Tolerability; Oncology; Randomized controlled trial; Interim analysis; Urology; Cancer; Adverse effect; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002138298,0.002105817,0.003011328,0.0008252461,0.0004857944,0.001075484,0.00161148,0.001983625,0.008288298],"category_scores_gemma":[0.001537318,0.0008771419,0.001593169,0.0005617748,0.001595376,0.0009682646,0.0005654233,0.003461541,0.001298457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006875539,"about_ca_system_score_gemma":0.001863143,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009603908,"about_ca_topic_score_gemma":0.001986315,"domain_scores_codex":[0.9993303,0.0003848246,0.00003151815,0.0001022683,0.00005347039,0.00009754678],"domain_scores_gemma":[0.9990861,0.0002004672,0.0001882637,0.00006430818,0.00005711065,0.0004036168],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9676824,0.01254591,0.000274784,0.0006904783,0.0005568892,0.00002497916,0.00003406278,0.000279078,0.003367433,0.0001359641,0.000914211,0.01349392],"study_design_scores_gemma":[0.9215859,0.0767555,0.0004833217,0.0000174505,0.0001546336,0.00001796594,0.000008659969,0.0001671361,0.0003647834,0.00005175803,0.0003830316,0.000009895646],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9778664,0.005926261,0.0008050599,0.0005859424,0.0006611556,0.009128181,0.00171577,0.0003725626,0.002938614],"genre_scores_gemma":[0.9712226,0.00431967,0.00303732,0.00125233,0.000550547,0.0120898,0.002047732,0.00004458831,0.005435484],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008288298,"threshold_uncertainty_score":0.02772713,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1176363502197273,"score_gpt":0.4702516051159598,"score_spread":0.3526152548962326,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}